drugset / Trial / NCT02064725
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent PrR-negative endometrial cancer.
Timeline
- Start
- 2014-09
- Primary completion
- 2018-01
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cridanimod | Small molecule | 500 mg | Intramuscular |
| Background | Megestrol Acetate | Other / unclassified | 160 mg | Oral |
| Background | medroxyprogesterone acetate | Other / unclassified | 200 mg | Oral |